Abstract
The ability of dexamethasone and prednisolone (corticosteroids), FK506 and cyclosporin A (T cell immunosuppressants), and of nitraquazone and rolipram (phosphodiesterase IV inhibitors) to inhibit cytokine production by stimulated human blood was investigated. Heparinized human blood obtained from normal healthy volunteers was stimulated with phytohemagglutinin (PHA) in the presence or absence of drug. After different incubation times, supernatant levels of interleukin (IL)-2, IL-5, granulocyte-macrophage colony stimulating factor (GM-CSF) and interferonγ (IFN-γ) were quantified by ELISA. Dexamethasone strongly inhibited the production of IL-5 (IC50 = 0.004 µM), was less potent against IL-2 and IFN-γ (IC50 = 0.02–0.05 µM) and showed a relatively weak effect against GM-CSF (IC50 = 0.6 µM). Similarly prednisolone potently suppressed IL-5 generation (IC50=0.05 µM), displayed a more modest activity on IL-2 and IFN-γ (IC50 = 0.2–0.3 µM) and exerted only partial effects (43% inhibition at 1 µM) on GM-CSF. FK506 strongly suppressed the production of IL-2 (IC50 = 0.01 µM) and GM-CSF (IC50 = 0.03 µM), but was inactive (<30% inhibition at 1 µM) against IL-5 and IFN-γ. Similarly, cyclosporin A reduced the generation of IL-2 (IC50 = 0.4 µM) and GM-CSF (IC50 = 0.6 µM) while barely affecting the other two cytokines. Nitraquazone and rolipram were most active in reducing the production of IL-5 (IC50 = 0.8 and 1.3 µM, respectively), while their potency against IL-2, GM-CSF and IFN-γ was 3–6 times lower, with IC50's between 2.4 and 8.0 µM. These data indicate that corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors affect cytokine production by PHA-stimulated human blood cells in a differential and “pharmacotypical” manner.
Similar content being viewed by others
References
Pahlavani MA. Cytokines in immunity and disease: therapeutic intervention. Drugs Today 1993;29:525–33.
Oppenheim JJ, Neta R. Pathophysiological roles of cytokines in development, immunity and inflammation. The FASEB J 1994;8:158–62.
Broide DH. Cytokines — orchestrators of human allergic reactions. ACI News 1994;6:12–4.
Smith KA. Interleukin 2: inception, impact and implications. Science 1988;240:1169–76.
Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood 1992;79:3101–9.
Takatsu K, Takaki S, Hitoshi Y. Interleukin-5 and its receptor system: implications in the immune system and inflammation. Adv Immunol 1994;57:145–90.
Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. New Engl J Med 1992;327:28–35.
Farrar MA, Schreiber RD. The molecular cell biology of interferon-γ and its receptor. Ann Rev Immunol 1993;11:571–611.
Henderson DJ, Naya I, Bundick V, Smith GM, Schmidt JA. Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. Immunol 1991;73:316–21.
Gillis S, Crabtree GR, Smith KA. Glucocorticoid-induced inhibition of T cell growth factor production. J Immunol 1979;123:1624–31.
Grabstein K, Dower S, Gillis S, Urdal D, Larsen A. Expression of interleukin 2, interferon-γ, and the IL-2 receptor by human peripheral blood lymphocytes. J Immunol 1986;136:4503–7.
Byron KA, Varigos G, Wootton A. Hydrocortisone inhibition of human interleukin-4. Immunol 1992;77:624–6.
Okayama H, Fushimi T, Shimura S, Sasaki H, Shirato K. Glucocorticoids suppressed production and gene expression of interleukin-5 by peripheral blood mononuclear cells in atopic patients and normal subjects. J All Clin Immunol 1994;93:1006–12.
Schmidt J, Fleissner S, Heimann-Weischat I, Lindstaedt R, Pomberg B, Werner U, et al. Effect of corticosteroids, cyclosporin A, and methotrexate on cytokine release from monocytes and T-cell subsets. Immunopharm 1994;27:173–9.
Elsässer-Beile U, Von Kleist S, Gallati H. Evaluation of a test system for measuring cytokine production in human whole blood cell cultures. J Immunol Meth 1991;139:191–5.
Allen JN, Herzyk DJ, Allen ED, Wewers MD. Human whole blood interleukin-1-β production: kinetics, cell source, and comparison with TNF-α. J Lab Clin Med 1992;119:538–46.
DeForge LE, Kenney JS, Jones ML, Warren JS, Remick DG. Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. J Immunol 1992;148:2133–41.
Vacca A, Felli MP, Farina AR, Martinotti S, Maroder M, Screpanti I, et al. Glucocorticoid receptor-mediated suppression of the interleukin-2 gene expression through impairment of the cooperativity between nuclear factor of activated T cells and AP-1 enhancer elements. J Exp Med 1992;175:637–46.
Northrop JP, Crabtree GR, Mattila PS. Negative regulation of interleukin 2 transcription by the glucocorticoid receptor. J Exp Med 1992;175:1235–45.
Rao A. NF-ATp: a transcription factor required for the coordinate induction of several cytokine genes. Immunol Today 1994;15:274–81.
Liu J. FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 1993;14:290–5.
Cardenas ME, Hemenway C, Muir RS, Ye R, Fiorentino D, Heitman J. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. EMBO J 1994;13:5944–57.
Tsuboi A, Muramatsu M, Tsutsumi A, Arai K, Arai N. Calcineurin activates transcription from the GM-CSF promoter in synergy with either protein kinase C or NF-kB/AP-1 in T cells. Bioch Biophys Res Comm 1994;2:1064–72.
Tsuboi A, Masuda ES, Naito Y, Tokumitsu H, Arai K, Arai N. Calcineurin potentiates activation of the granulocyte-macrophage colony-stimulating factor gene in T cells: involvement of the conserved lymphokine element O. Mol Biol Cell 1994;5:119–28.
Faulds D, Goa KL, Benfield K. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993;45:953–1040.
Andersson J, Nagy S, Groth C-G, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studiedin vitro at a single-cell level. Immunol 1992;75:136–42.
Szamel M, Resch K. T-cell antigen receptor-induced signal transduction pathways. Eur J Biochem 1995;228:1–15.
Raeburn D, Souness JE, Tomkinson A, Karlsson JA. Isoenzymeselective cyclic nucleotide phosphodiesterase inhibitors: biochemistry, pharmacology and therapeutical potential in asthma. Prog Drug Res 1993;40:9–32.
Lalli E, Sassone-Corsi P. Signal transduction and gene regulation: the nuclear response to cAMP. J Biol Chem 1994;269:17359–62.
Daum G, Eisenmann-Tappe I, Fries H-W, Troppmair J, Rapp UR. The ins and outs of Raf kinases. TIBS 1994;19:474–80.
Hafner S, Adler HS, Mischak H, Janosch P, Heidecker G, Wolfman A, et al. Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol 1994;14:6696–703.
Paliogianni F, Kincaid RL, Boumpas DT. Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin-dependent pathways. J Exp Med 1993;178:1813–7.
Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int J Immunopharm 1993;15:409–13.
Molnar-Kimber KL, Yonno L, Heaslip RJ, Weichman BM. Differential regulation of TNF-α and IL-1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Med Inflamm 1992;1:441–417.
Prabhakar U, Lipshutz D, O'Leary Bartus J, Slivjak MJ, Smith III EF, Lee JC, et al. Characterization of cAMP-dependent inhibition of LPS-induced-TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int J Immunopharm 1994;16:805–16.
Verghese MW, McConnell RT, Strickland AB, Gooding RC, Stimpson SA, Yarnall DP, et al. Differentiation regulation of human monocyte-derived TNFα and IL-1β by Type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J Pharmacol Exp Ther 1994;272:1313–20.
Giembycz MA. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol 1992;43:2041–51.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van Wauwe, J., Aerts, F., Walter, H. et al. Cytokine production by phytohemagglutinin-stimulated human blood cells: Effects of corticosteroids, T cell immunosuppressants and phosphodiesterase IV inhibitors. Inflamm Res 44, 400–405 (1995). https://doi.org/10.1007/BF01797868
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01797868